Anti-HIV-1 gp120 Reference Antibody (Lotivibart, RUO) (VK645036)

Name: Anti-HIV-1 gp120 Reference Antibody (Lotivibart, RUO)
Brand: abinScience
SKU: VK645036
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	VK645036
Description	lotivibart (VK645036) is a research-grade recombinant antibody targeting gp120/Glycoprotein 120. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research.
Reactivité des espèces	Human immunodeficiency virus type 1 (HIV-1)
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG1, Kappa
Espèces	Human immunodeficiency virus 1 (HIV-1)
Cible	gp120/Glycoprotein 120
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Numéro d'accès	Q03805
Forme	Liquid
Reconstitution	Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Expédition	In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	2851892-98-1
Contexte	Envelope glycoprotein gp160 (gp120/Glycoprotein 120) is a ~96 kDa protein. Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.
Note	For research use only. Not suitable for clinical or therapeutic use.